baha the information company

baha is a leading provider of real-time market data, financial news, technology and solutions for the financial industry. baha offers real-time data terminals for professionals, global financial market data covering over 12 million financial instruments on more than 150 exchanges, as well as 24/7 breaking news with global coverage and free web and mobile apps. From a total of around 200 real-time data providers worldwide, only Reuters 1851, Bloomberg 1981 and now baha in 2021 were named after the founder.

Ocuphire Pharma Inc/ US67577R1023 /

2024-05-10 9:54:05 PM	Chg. -0.25	Volume	Bid-	Ask-	High	Low
1.70USD	-12.63%	5,658 Turnover: 10,441.37	-Bid Size: -	-Ask Size: -	1.95	1.70

GlobeNewswire 05-10 Ocuphire Pharma Announces Financial Results for First Quarter 2024 and Provides Corporate Update

GlobeNewswire 05-06 Ocuphire Pharma Announces Presentation on APX3330 at the ARVO 2024 Annual Meeting

GlobeNewswire 05-03 Ocuphire Pharma to Present at the Aegis Virtual Conference

GlobeNewswire 04-22 Ocuphire Pharma Announces APX3330 Presentation at ARVO 2024 Annual Meeting

GlobeNewswire 04-11 First Patient Enrolled in LYNX-2 Phase 3 Study Evaluating Phentolamine Ophthalmic Solution 0.75% (PS...

GlobeNewswire 04-01 Ocuphire Announces the U.S. Commercial Launch of RYZUMVl™ (Phentolamine Ophthalmic Solution 0.75%) b...

GlobeNewswire 03-08 Ocuphire Pharma Announces Financial Results for Fourth Quarter and Full Year 2023 and Provides Corpo...

GlobeNewswire 02-23 Ocuphire Pharma to Present in the BIO CEO & Investor Conference

GlobeNewswire 02-15 Ocuphire Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire 02-14 Ocuphire Pharma Strengthens Leadership Team with Key Appointments

GlobeNewswire 02-05 Ocuphire Pharma Announces Presentation on APX3330 at the Annual Angiogenesis, Exudation, and Degener...

GlobeNewswire 01-24 Ocuphire Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire 01-04 Ocuphire Pharma Receives FDA Agreement Under Special Protocol Assessment for LYNX-2 Phase 3 Trial of...

GlobeNewswire 2023-11-30 Ocuphire Pharma Announces Presentation at Ophthalmology Innovation Summit (OIS) XIII

GlobeNewswire 2023-11-27 Ocuphire Pharma Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire 2023-11-27 Ocuphire Pharma Announces Appointment of Joseph Schachle, M.B.A., as Chief Operating Officer

GlobeNewswire 2023-11-13 Ocuphire Pharma Announces Financial Results for Third Quarter 2023 and Provides Corporate Update

GlobeNewswire 2023-11-02 Ocuphire Pharma Announces Successful End-of-Phase 2 Meeting with FDA for Oral APX3330 in Diabetic Re...

GlobeNewswire 2023-11-01 Ocuphire Pharma Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire 2023-11-01 Ocuphire Pharma Announces Appointment of George Magrath, M.D., M.B.A., M.S., as Chief Executive Offi...

GlobeNewswire 2023-10-26 Ocuphire Pharma to Present at AAO 2023 and Eyecelerator Retina Showcase

GlobeNewswire 2023-10-06 Ocuphire Pharma to Present at Euretina and Retina Society Conferences in October

GlobeNewswire 2023-09-27 Ocuphire Pharma and Viatris Announce FDA Approval of RYZUMVI™ (Phentolamine Ophthalmic Solution) 0.7...

GlobeNewswire 2023-09-11 Ocuphire Pharma to Participate in Three Upcoming Investment Bank Conferences

GlobeNewswire 2023-09-07 Ocuphire Pharma to Present at ESCRS 2023 and MODLive! Conferences in September

Ocuphire Pharma Inc/ US67577R1023 /

If you wish to receive reply to your feedback, please provide your email address.